|1.||Gandhi, Varsha: 3 articles (12/2007 - 10/2002)|
|2.||Ueda, Takanori: 2 articles (04/2013 - 06/2009)|
|3.||Yamauchi, Takahiro: 2 articles (04/2013 - 06/2009)|
|4.||Negoro, Eiju: 2 articles (04/2013 - 06/2009)|
|5.||Lamba, Jatinder K: 2 articles (10/2009 - 12/2007)|
|6.||Plunkett, William: 2 articles (12/2007 - 10/2002)|
|7.||Matherly, Larry H: 2 articles (02/2005 - 01/2004)|
|8.||Taub, Jeffrey W: 2 articles (02/2005 - 01/2004)|
|9.||Ravindranath, Yaddanapudi: 2 articles (02/2005 - 01/2004)|
|10.||Ge, Yubin: 2 articles (02/2005 - 01/2004)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
02/01/1990 - "Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia."
12/15/1987 - "The pharmacodynamic parameters of ara-CTP in circulating blast cells were more homogeneous in patients with ANLL than in patients with ALL. "
12/15/1987 - "The elimination kinetics of ara-CTP was monoexponential with t1/2,el of 3.30 +/- 0.8 h and 6.9 +/- 2.8 h in patients with ANLL and ALL. "
12/15/1987 - "The intracellular peak concentration of ara-CTP in circulating blast cells averaged 432.2 +/- 14.5 microM and 544.3 +/- 330 microM in patients with ANLL and ALL, respectively. "
09/01/2001 - "Here, using our new sensitive method, we evaluated the ara-CTP pharmacokinetics in relation to the therapeutic response in 11 acute myelogenous leukemia patients who received a 2-h infusion of BHAC (70 mg / m(2)) in combination remission induction therapy. "
|2.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
08/01/2009 - "Because cladribine can increase cytarabine triphosphate levels, we tested a cladribine-cytarabine combination in the St Jude AML97, trial in which this combination was administered before standard chemotherapy to 96 children with acute myeloid leukemia (AML) or myelodysplastic syndrome. "
01/01/2004 - "Since leukemic cells primed by exposure to fludarabine exhibit enhanced accumulation of cytarabine triphosphate (the cytotoxic nucleotide of cytarabine), especially with continuous cytarabine (AraC) infusion, a phase II trial was designed to explore the feasibility and efficacy of a combination chemotherapy associating fludarabine, mitoxantrone (MXN), and high-dose cytarabine (continuous infusion) for high-risk P glycoprotein (PGP)-negative myelodysplastic syndromes (MDS) (FAM protocol). "
08/01/2002 - "Total body clearance of F-ara-A (main circulating metabolite of fludarabine) is linked to creatinine clearance and drug-related neutropenia are more frequent in patients with creatinine clearance below 50 mL/min. So far there are no relationships between intracellular levels of F-ara-CTP and response to treatment."
06/01/1988 - "The studies described in this review were selected as representative examples of successful clinical pharmacodynamic studies; other published examples include vincristine AUC versus severity of neurotoxicity, etoposide systemic exposure versus leukopenia, red cell concentration of mercaptopurine metabolites versus neutropenia in children with ALL, and ARA-CTP retention in leukemic blasts versus clinical response in acute non-lymphocytic leukemia. "
07/15/1990 - "1-beta-D-Arabinofuranosylcytosine 5'-triphosphate (ara-CTP) levels were elevated (greater than 500 pmol/10(7) cells) in L1210 leukemia cells within 1 h following i.p. "
01/01/1975 - "It appears that the differential net tissue level of ara-CTP and its duration are the determinants of chemotherapeutic efficacy of ara-C against L1210 leukemia. "
12/01/1992 - "In the least responsive tumor (P-388), although Ara-CTP pools were sufficiently high, retention of the drug in tumor cells and in normal cells is poor with a T1/2 < 2 hr. Thus, unlike mice bearing leukemia L1210 cells, alteration of the mode and dose of administration of Ara-C in mice bearing P-388 could only result in increased host toxicity with no therapeutic gain. "
01/01/1990 - "Our studies demonstrate a significant correlation between clinical response and the pharmacokinetics of Ara-CTP in leukemia cells during therapy. "
01/01/1987 - "In this study accumulation and cellular retention of ara-CTP have been measured in vitro in the bone marrow cells of 69 patients with acute leukemia. "
01/01/2012 - "The concentration of intracellular ara-CTP and incorporated ara-CTP were monitored in human leukemia cell line-HL-60 for different passages in parental with its variant HL-60R. "
01/01/2004 - "Intracellular levels of Ara-CTP measured by HPLC were increased 1.5-3 fold in leukemia cells with most promiment effects in HL-60, Kasumi and Raji cells. "
07/01/1996 - "The pharmacokinetics of Ara-CTP in leukemic cells was reported to be of clinical importance in adult nonlymphoblastic leukemia. "
|7.||triphosphoric acid (triphosphate)
|8.||DNA (Deoxyribonucleic Acid)
|10.||Etoposide (VP 16)
|1.||Combination Drug Therapy (Combination Chemotherapy)
|2.||Drug Therapy (Chemotherapy)